CLINICAL TRIALS PROFILE FOR METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE
✉ Email this page to a colleague
All Clinical Trials for METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00121641 ↗ | Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise | Completed | AstraZeneca | Phase 3 | 2005-07-01 | The purpose of this clinical research study is to learn whether saxagliptin (BMS-477118) is more effective than placebo as a treatment for type 2 diabetic subjects who are not sufficiently controlled with diet and exercise |
| NCT00121667 ↗ | Study Assessing Saxagliptin Treatment In Type 2 Diabetic Subjects Who Are Not Controlled With Metformin Alone | Completed | AstraZeneca | Phase 3 | 2005-08-01 | The purpose of this clinical research study is to learn whether Saxagliptin added to Metformin therapy is more effective than Metformin alone as a treatment for type 2 diabetic subjects who are not sufficiently controlled with Metformin alone |
| NCT00327015 ↗ | A Phase 3 Study of BMS-477118 in Combination With Metformin in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise | Completed | AstraZeneca | Phase 3 | 2006-05-01 | The purpose of this trial is to understand if adding saxagliptin to metformin therapy is safe and works better than taking either saxagliptin or metformin alone |
| NCT00575588 ↗ | 52-week add-on to Metformin Comparison of Saxagliptin and Sulphonylurea, With a 52-week Extension Period | Completed | Bristol-Myers Squibb | Phase 3 | 2007-12-01 | Saxagliptin is a new investigational medication being developed for treatment of type 2 diabetes. This study is designed to assess the efficacy and tolerability of saxagliptin in addition to metformin and compare to sulphonylurea in addition with metformin. |
| NCT00575588 ↗ | 52-week add-on to Metformin Comparison of Saxagliptin and Sulphonylurea, With a 52-week Extension Period | Completed | AstraZeneca | Phase 3 | 2007-12-01 | Saxagliptin is a new investigational medication being developed for treatment of type 2 diabetes. This study is designed to assess the efficacy and tolerability of saxagliptin in addition to metformin and compare to sulphonylurea in addition with metformin. |
| NCT00661362 ↗ | Evaluate Efficacy and Safety of Saxagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes | Completed | Bristol-Myers Squibb | Phase 3 | 2008-06-01 | Saxagliptin is a new investigational medication being developed for treatment of type 2 diabetes. This study is designed to evaluate the efficacy and safety in adult patients who have inadequate glycaemic control when treated with metformin in addition to diet and exercise. |
| NCT00661362 ↗ | Evaluate Efficacy and Safety of Saxagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes | Completed | AstraZeneca | Phase 3 | 2008-06-01 | Saxagliptin is a new investigational medication being developed for treatment of type 2 diabetes. This study is designed to evaluate the efficacy and safety in adult patients who have inadequate glycaemic control when treated with metformin in addition to diet and exercise. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE
Condition Name
Condition MeSH
Clinical Trial Locations for METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE
Trials by Country
Clinical Trial Progress for METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE
Clinical Trial Phase
Clinical Trial Sponsors for METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE
Sponsor Name
